Search published articles


Showing 2 results for Levothyroxine

Zahra Shiravand, Afsaneh Talaei,
Volume 22, Issue 4 (9-2019)
Abstract

Background and Aim Thyroid diseases are among the most common endocrine disorders. Animal and human experiences indicate that iron deficiency disrupts thyroid metabolism. On the other hand, iron therapy can improve thyroid function and even decrease the dose of levothyroxine.
Methods and Materials In this randomized clinical trial, we selected 94 women with hypothyroidism by simple random sampling method and divided them into two equal groups by simple block sampling. At the beginning of the study, we measured and recorded T4, TSH, T3, and iron profiles (Serum iron, total iron-binding capacity, ferritin, Hemoglobin) in all patients. Then, the patients in the intervention group were treated with levothyroxine plus 100 mg oral iron daily for 8 weeks, and the patients in the control group were treated with levothyroxine only. After two months, we measured their T4, TSH, T3 levels and iron profiles in both groups again.
Ethical Considerations The Research Ethics Committee of Arak University of Medical Sciences approved this study (Research Ethics Code: 1396154). Also, the study has been registered at the Iranian Registry of Clinical Trials (Code: IRCT 20151114025031).
Results After 2 months, the TSH Mean±SD serum levels were found as 2.2±1.0 mIU/L and 2.9±1.1 mIU/L for the intervention and control group, respectively (P=0.04). Also, the serum Mean±SD level of T4 and T3 were found as 9.3±1.48 mcg/dL vs. 8.2±0.9 mcg/dL (P=0.01), and 1.6±0.3 ng/mL vs. 1.1±0.3 ng/mL (P=0.01), for two different groups, respectively. 
Conclusion Concurrent administration of iron supplementation with the usual dose of levothyroxine in patients with hypothyroidism decreases THS level and improves laboratory parameters and response to treatment.

Afsaneh Talaei, Fatemeh Rafiei, Glonaz Motamedi, Ali Chehrei,
Volume 28, Issue 2 (4-2025)
Abstract

Introduction: Thyroid nodules are highly prevalent. The role of insulin resistance in thyroid nodule formation has recently gained attention. While several studies have explored the relationship between metformin and insulin resistance, limited research has assessed the effect of metformin therapy on thyroid nodule volume and number. This study investigated the effect of metformin on the size and number of thyroid nodules.
Methods: A total of 240 euthyroid women with thyroid nodules were divided into four groups. Group 1 received levothyroxine 100 μg/day, Group 2 received metformin 500 mg twice daily, Group 3 received a combination of both drugs for three months, and Group 4 served as the control group with no treatment. Thyroid ultrasound was performed at baseline and after three months. Statistical analyses included the Kruskall–Wallis, Wilcoxon, and Chi-square tests, examined the differences of the size of thyroid nodules and the mean of thyroid hormones levels between groups, for Each group included 60 people and to compare the percentage of differences between the groups, respectively. Also P value less than 0.05 was considered meaningful.
Results: Results showed no statistically significant differences in thyroid hormone levels after treatment among the three groups except the levothyroxine group. Additionally, only the levothyroxine group showed a significant post-treatment decrease in TSH and increase in T4. Thyroid nodule size significantly decreased in the levothyroxine group and the levothyroxine-metformin combination group compared to the metformin-alone and control groups.
Conclusions: This study indicates that metformin does not reduce the size of thyroid nodules, contradicting studies suggesting its potential antineoplastic effects on the thyroid. However, the study duration may be insufficient for definitive conclusions, necessitating further high-quality studies with larger sample sizes and longer follow-up periods.
 

Page 1 from 1     

© 2025 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb